Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$73.78 USD
-0.56 (-0.75%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $73.77 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$73.78 USD
-0.56 (-0.75%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $73.77 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
Zacks News
Top Stock Reports for Toyota, CVS Health & 3M
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Toyota Motor (TM), CVS Health (CVS) and 3M (MMM).
Gilead (GILD) Announces Positive Long-Term Data on Yescarta
by Zacks Equity Research
Gilead (GILD) announces positive long-term data from a mid-stage study on Yescarta in adult patients with refractory large B-cell lymphoma.
Glaxo Files NDA for Fostemsavir for Heavily Pre-Treated HIV
by Zacks Equity Research
Glaxo (GSK) submits a new drug application to the FDA for its first-in-class attachment inhibitor fostemsavir, which is being evaluated for the treatment of HIV-1 infection.
Intercept (ICPT) Gains 7.5% YTD on Progress in NASH Space
by Zacks Equity Research
Intercept (ICPT) stock gains as it becomes the forerunner in the NASH drug race.
Intercept's (ICPT) NDA for NASH Drug Gets Priority Review
by Zacks Equity Research
Intercept (ICPT) obtains Priority Review for its NDA for OCA in the United States for the treatment of fibrosis due to NASH.
AstraZeneca Gets FDA Nod for Calquence Line Extension in CLL
by Zacks Equity Research
The FDA approves AstraZeneca's (AZN) Calquence to treat CLL patients, based on positive data from two phase III studies.
Biotech ETF (BBH) Hits New 52-Week High
by Sweta Killa
This biotech ETF hits a new 52-week high. Are more gains in store for this ETF?
Biotech Stock Roundup: SLDB Plunges, CELG Gets FDA Nod for Reblozyl & Other Updates
by Zacks Equity Research
Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.
The Zacks Analyst Blog Highlights: Toyota, Netflix, AbbVie, Gilead and Fiserv
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Toyota, Netflix, AbbVie, Gilead and Fiserv
Top Research Reports for Toyota, Netflix & AbbVie
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Toyota Motor (TM), Netflix (NFLX) and AbbVie (ABBV).
Agenus (AGEN) Q3 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Agenus (AGEN) posts narrower-than-expected loss and beats sales estimates in the third quarter of 2019.
Biotech ETFs in Focus on Impressive Q3 Earnings Results
by Sweta Jaiswal, FRM
Let's take a look at some ETFs with wide exposure to a few biotechnological companies which released solid Q3 earnings results recently.
The Zacks Analyst Blog Highlights: Alexion, Amgen, Gilead and AMAG
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alexion, Amgen, Gilead and AMAG
Biotech Stock Roundup: Q3 Earnings Beat at ALXN & AMGN, Pipeline Updates & More
by Zacks Equity Research
Key highlights include earnings updates, collaboration deals, and regulatory and pipeline updates.
Drug/Biotech Stock Q3 Earnings Due on Oct 29: MRK, PFE & More
by Zacks Equity Research
Four drug/biotech stocks are scheduled to release third-quarter results on Oct 29. Let's see how these companies are placed before their earnings call.
Callaway Golf, FedEx, Amazon, Intel and Gilead highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Callaway Golf, FedEx, Amazon, Intel and Gilead highlighted as Zacks Bull and Bear of the Day
Gilead's (GILD) Earnings Miss Estimates in Q3, Sales Beat
by Zacks Equity Research
Gilead (GILD) falls short of earnings estimates but marginally beats on sales in the third quarter of 2019.
Q3 Earnings Frenzy: Amazon (AMZN), Intel (INTC) & More
by Mark Vickery
Amazon missed earnings estimates, while Intel beat again and Gilead was in-line with expectations.
Gilead Sciences (GILD) Misses Q3 Earnings Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of -0.57% and 0.10%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Why Gilead (GILD) Might Surprise This Earnings Season
by Zacks Equity Research
Gilead (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
The Zacks Analyst Blog Highlights: U.S. Bancorp, Bristol-Myers Squibb, Morgan Stanley, Bank of America and Gilead Sciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: U.S. Bancorp, Bristol-Myers Squibb, Morgan Stanley, Bank of America and Gilead Sciences
Will Strong Jakafi Sales Drive Incyte's (INCY) Q3 Earnings?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports third-quarter 2019 results.
Top Stock Reports for U.S. Bancorp, Bristol-Myers Squibb & Morgan Stanley
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including U.S. Bancorp (USB), Bristol-Myers Squibb (BMY) and Morgan Stanley (MS).
Exact Sciences (EXAS) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
During Exact Sciences' (EXAS) third-quarter 2019 conference call, investor focus will be on the volume growth rate of its non-invasive screening test for colorectal cancer, Cologuard.
What's in Store for Healthcare ETFs in Q3 Earnings?
by Sweta Killa
With earnings surprise in the cards, the healthcare sector is expected to witness modest earnings growth of 0.3% in the third quarter, suggesting some room for potential upside for healthcare ETFs.